LUND, SWEDEN--(Marketwire - September 30, 2010) -
The number of shares and votes in Active Biotech has changed as a result of the exercise of employee stock options.
Today, the last trading day of the month, there are in total 65,967,864 shares and votes in Active Biotech.
Lund, September 30, 2010
Active Biotech AB (publ)
For further information, please contact: Hans Kolam, CFO Tel: +46 (0)46 19 20 44 E-mail:hans.kolam@activebiotech.com
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in or entering pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn’s and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57-57 for SLE & Systemic Sclerosis and RhuDex™ for RA. Please visitwww.activebiotech.com for more information.
Active Biotech AB PO Box 724, SE-220 07 Lund Sweden Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00
Active Biotech is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 08:30 a.m. CET on September 30, 2010.
[HUG#1445803]
Number of shares and votes in Active Biotech: http://hugin.info/1002/R/1445803/388952.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
